EPISODE · Feb 19, 2025 · 5 MIN
ASCO GU25 special: Dr. Houede discusses the iNDUCT trial
from EAU Podcasts · host European Association of Urology
In this podcast interview recorded at ASCO GU25, UROONCO bladder cancer chief editor Dr. Benjamin Pradere talked to Dr. Nadine Houede from CHU Nîmes, Hospital Caremeau in France, on the results of the iNDUCT trial. The iNDUCT trial is a phase II trial evaluated safety and efficacy of neoadjuvant chemotherapy (cisplatin or carboplatin + gemcitabine) in combination with durvalumab in these patients. Dr. Houede discusses the rational, the results and next steps. For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.
What this episode covers
In this podcast interview recorded at ASCO GU25, UROONCO bladder cancer chief editor Dr. Benjamin Pradere talked to Dr. Nadine Houede from CHU Nîmes, Hospital Caremeau in France, on the results of the iNDUCT trial. The iNDUCT trial is a phase II trial evaluated safety and efficacy of neoadjuvant chemotherapy (cisplatin or carboplatin + gemcitabine) in combination with durvalumab in these patients. Dr. Houede discusses the rational, the results and next steps. For more EAU podcasts...
NOW PLAYING
ASCO GU25 special: Dr. Houede discusses the iNDUCT trial
No transcript for this episode yet
Similar Episodes
Jun 15, 2022 ·8m
May 25, 2022 ·20m
May 19, 2022 ·16m
May 15, 2022 ·34m
May 12, 2022 ·1m